Clinical Trial Update: Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sorafenib as adjuvant therapy with radioiodine for non-medullary thyroid carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED